What is Leniolisib and How is it Synthesized?
Leniolisib is a medication that inhibits phosphoinositide 3-kinase delta (PI3Kδ) and is used to treat activated PI3K-delta syndrome (APDS) [1]. The synthesis of leniolisib involves several chemical steps and reagents. While specific proprietary synthesis routes are not publicly detailed by the manufacturer, general synthetic chemistry principles can illuminate the process. Typically, the synthesis of such complex molecules involves coupling key intermediates, often through reactions like nucleophilic substitution, amide formation, or cross-coupling reactions. The precise reagents and reaction conditions are optimized for yield, purity, and scalability.
What are the Key Chemical Components of Leniolisib?
Leniolisib's chemical structure is 2-((S)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-methylpropan-1-ol [1]. This structure features a pyrazolo[3,4-d]pyrimidine core, substituted with a phenoxyphenyl group and an amino group. A piperidine ring is attached to the pyrimidine core, and this piperidine is further substituted with a 2-methylpropan-1-ol moiety. Each of these structural components would be assembled through distinct synthetic pathways before being brought together.
When Does Leniolisib's Patent Protection Expire?
Patent protection for leniolisib is a critical factor for its market exclusivity. DrugPatentWatch.com tracks patent information for pharmaceuticals, providing data on patent expiry dates and potential challenges [2]. Understanding these dates is crucial for predicting when generic or biosimilar versions might become available. Specific patent expiry timelines for leniolisib would need to be consulted on resources like DrugPatentWatch.com for the most accurate and up-to-date information [2].
Who Manufactures Leniolisib?
Leniolisib is developed and manufactured by Secura Bio, Inc. [3]. The company has been instrumental in bringing this treatment to market for patients with APDS.